Login to Your Account


OXFORD, U.K. – The increasing level of funding dedicated to the commercialization of university research is indicative of progress, but the U.K. is not quite there in terms of translating knowledge that is the fruit of publicly funded research into real benefits.

LONDON – Actelion Ltd. added a positive EMA opinion to the FDA and Health Canada approvals for its first-in-class, selective prostacyclin IP receptor agonist, Uptravi (selexipag), for treating pulmonary arterial hypertension (PAH).

LONDON – The question of to what extent those who meet the inclusion criteria in randomized controlled trials (RCTs) match the likely patient population is nowhere more marked than in respiratory diseases.

More EUROPE Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: